Literature DB >> 21402849

Evaluation of the mean corpuscular volume of peripheral blood mononuclear cells of HIV patients by a coulter counter to determine intracellular drug concentrations.

Marco Simiele1, Antonio D'Avolio, Lorena Baietto, Marco Siccardi, Mauro Sciandra, Silvia Agati, Jessica Cusato, Stefano Bonora, Giovanni Di Perri.   

Abstract

The mean corpuscular volume (MCV) of peripheral blood mononuclear cells (PBMCs) was determined by Coulter Counter, and data were used to calculate the intracellular drug concentrations. A total of 574 PBMC samples were collected from 190 patients. The MCV was 282.9 fl (minimum, 207.0; maximum, 354.6), with a standard deviation of 8.8%. Previous reports have often used a fixed value of 400 fl for the MCV, which may result in artificially low estimates of the intracellular concentrations of antivirals.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21402849      PMCID： PMC3101420          DOI： 10.1128/AAC.01236-10

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  13 in total

1.  A strategy for liquid chromatography/tandem mass spectrometric assays of intracellular drugs: application to the validation of the triphosphorylated anabolite of antiretrovirals in peripheral blood mononuclear cells.

Authors:  François Becher; Alain Pruvost; Jane Gale; Philippe Couerbe; Cécile Goujard; Valerie Boutet; Eric Ezan; Jacques Grassi; Henri Benech
Journal:  J Mass Spectrom       Date:  2003-08       Impact factor: 1.982

2.  A HPLC-MS method for the simultaneous quantification of fourteen antiretroviral agents in peripheral blood mononuclear cell of HIV infected patients optimized using medium corpuscular volume evaluation.

Authors:  Antonio D'Avolio; Marco Simiele; Marco Siccardi; Lorena Baietto; Mauro Sciandra; Valentina Oddone; Francesca Romana Stefani; Silvia Agati; Jessica Cusato; Stefano Bonora; Giovanni Di Perri
Journal:  J Pharm Biomed Anal       Date:  2010-11-10       Impact factor: 3.935

Review 3.  ABC transporters in human lymphocytes: expression, activity and role, modulating factors and consequences for antiretroviral therapies.

Authors:  Carole Giraud; Sandra Manceau; Jean-Marc Treluyer
Journal:  Expert Opin Drug Metab Toxicol       Date:  2010-05       Impact factor: 4.481

4.  Intracellular and plasma steady-state pharmacokinetics of raltegravir, darunavir, etravirine and ritonavir in heavily pre-treated HIV-infected patients.

Authors:  Rob Ter Heine; Jan Willem Mulder; Eric C M van Gorp; Jiri F P Wagenaar; Jos H Beijnen; Alwin D R Huitema
Journal:  Br J Clin Pharmacol       Date:  2010-05       Impact factor: 4.335

5.  Intracellular accumulation of human immunodeficiency virus protease inhibitors.

Authors:  Saye H Khoo; Patrick G Hoggard; Ian Williams; E Rhiannon Meaden; Philippa Newton; Edmund G Wilkins; Alan Smith; John F Tjia; Judy Lloyd; Kevin Jones; Nick Beeching; Peter Carey; Barry Peters; David J Back
Journal:  Antimicrob Agents Chemother       Date:  2002-10       Impact factor: 5.191

Review 6.  Intracellular Pharmacokinetics of Antiretroviral Drugs in HIV-Infected Patients, and their Correlation with Drug Action.

Authors:  Caroline Bazzoli; Vincent Jullien; Clotilde Le Tiec; Elisabeth Rey; France Mentré; Anne-Marie Taburet
Journal:  Clin Pharmacokinet       Date:  2010       Impact factor: 6.447

7.  Low levels of deoxynucleotides in peripheral blood lymphocytes: a strategy to inhibit human immunodeficiency virus type 1 replication.

Authors:  W Y Gao; A Cara; R C Gallo; F Lori
Journal:  Proc Natl Acad Sci U S A       Date:  1993-10-01       Impact factor: 11.205

8.  Cellular volume and marker expression in human peripheral blood apheresis stem cells.

Authors:  Siddharth Sharma; Raquel Cabana; Sherry Shariatmadar; Awtar Krishan
Journal:  Cytometry A       Date:  2008-02       Impact factor: 4.355

9.  Quantification of HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors in peripheral blood mononuclear cell lysate using liquid chromatography coupled with tandem mass spectrometry.

Authors:  R ter Heine; M Davids; H Rosing; E C M van Gorp; J W Mulder; Y T van der Heide; J H Beijnen; A D R Huitema
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2009-01-14       Impact factor: 3.205

10.  Specificity enhancement with LC-positive ESI-MS/MS for the measurement of nucleotides: application to the quantitative determination of carbovir triphosphate, lamivudine triphosphate and tenofovir diphosphate in human peripheral blood mononuclear cells.

Authors:  Alain Pruvost; Frédéric Théodoro; Luigi Agrofoglio; Eugenia Negredo; Henri Bénech
Journal:  J Mass Spectrom       Date:  2008-02       Impact factor: 1.982
View more
  28 in total

1.  A novel ultrasensitive LC-MS/MS assay for quantification of intracellular raltegravir in human cell extracts.

Authors:  Brian L Robbins; Sarah R Nelson; Courtney V Fletcher
Journal:  J Pharm Biomed Anal       Date:  2012-06-02       Impact factor: 3.935

2.  Pharmacokinetic Modeling of Lamivudine and Zidovudine Triphosphates Predicts Differential Pharmacokinetics in Seminal Mononuclear Cells and Peripheral Blood Mononuclear Cells.

Authors:  Julie B Dumond; Kuo H Yang; Racheal Kendrick; Y Sunila Reddy; Angela D M Kashuba; Luigi Troiani; Arlene S Bridges; Susan A Fiscus; Alan Forrest; Myron S Cohen
Journal:  Antimicrob Agents Chemother       Date:  2015-08-03       Impact factor: 5.191

3.  Exploring the intracellular pharmacokinetics of the 5-fluorouracil nucleotides during capecitabine treatment.

Authors:  Ellen J B Derissen; Bart A W Jacobs; Alwin D R Huitema; Hilde Rosing; Jan H M Schellens; Jos H Beijnen
Journal:  Br J Clin Pharmacol       Date:  2016-03-02       Impact factor: 4.335

4.  Correlation between plasma, intracellular, and cervical tissue levels of raltegravir at steady-state dosing in healthy women.

Authors:  Caroline Mitchell; Emily Roemer; Evangelyn Nkwopara; Brian Robbins; Theodore Cory; Tessa Rue; Courtney V Fletcher; Lisa Frenkel
Journal:  Antimicrob Agents Chemother       Date:  2014-03-31       Impact factor: 5.191

5.  Pharmacokinetic modeling of plasma and intracellular concentrations of raltegravir in healthy volunteers.

Authors:  Lingzhi Wang; Gaik Hong Soon; Kok-Yong Seng; Jun Li; Edmund Lee; Eu-Leong Yong; Boon-Cher Goh; Charles Flexner; Lawrence Lee
Journal:  Antimicrob Agents Chemother       Date:  2011-07-11       Impact factor: 5.191

6.  Simultaneous population pharmacokinetic modelling of plasma and intracellular PBMC miltefosine concentrations in New World cutaneous leishmaniasis and exploration of exposure-response relationships.

Authors:  Anke E Kip; María Del Mar Castro; Maria Adelaida Gomez; Alexandra Cossio; Jan H M Schellens; Jos H Beijnen; Nancy Gore Saravia; Thomas P C Dorlo
Journal:  J Antimicrob Chemother       Date:  2018-08-01       Impact factor: 5.790

7.  Long-Acting Profile of 4 Drugs in 1 Anti-HIV Nanosuspension in Nonhuman Primates for 5 Weeks After a Single Subcutaneous Injection.

Authors:  Lisa A McConnachie; Loren M Kinman; Josefin Koehn; John C Kraft; Sarah Lane; Wonsok Lee; Ann C Collier; Rodney J Y Ho
Journal:  J Pharm Sci       Date:  2018-03-13       Impact factor: 3.534

8.  A Cyclic Phosphoramidate Prodrug of 2'-Deoxy-2'-Fluoro-2'-C-Methylguanosine for the Treatment of Dengue Virus Infection.

Authors:  Ratna Karuna; Fumiaki Yokokawa; Keshi Wang; Jin Zhang; Haoying Xu; Gang Wang; Mei Ding; Wai Ling Chan; Nahdiyah Abdul Ghafar; Andrea Leonardi; Cheah Chen Seh; Peck Gee Seah; Wei Liu; Rao P S Srinivasa; Siew Pheng Lim; Suresh B Lakshminarayana; Ellie Growcott; Sreehari Babu; Martijn Fenaux; Weidong Zhong; Feng Gu; Pei-Yong Shi; Francesca Blasco; Yen-Liang Chen
Journal:  Antimicrob Agents Chemother       Date:  2020-11-17       Impact factor: 5.191

9.  Pharmacokinetic Changes during Pregnancy According to Genetic Variants: a Prospective Study in HIV-Infected Patients Receiving Atazanavir-Ritonavir.

Authors:  Emanuele Focà; Andrea Calcagno; Andrea Bonito; Jessica Cusato; Elisabetta Domenighini; Antonio D'Avolio; Eugenia Quiros Roldan; Laura Trentini; Filippo Castelnuovo; Giovanni Di Perri; Francesco Castelli; Stefano Bonora
Journal:  Antimicrob Agents Chemother       Date:  2018-06-26       Impact factor: 5.191

10.  Increasing extracellular protein concentration reduces intracellular antiretroviral drug concentration and antiviral effect.

Authors:  Lindsay B Avery; Melissa A Zarr; Rahul P Bakshi; Robert F Siliciano; Craig W Hendrix
Journal:  AIDS Res Hum Retroviruses       Date:  2013-05-22       Impact factor: 2.205
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.